2017
In vitro and in vivo investigations into the carbene gold chloride and thioglucoside anticancer drug candidates NHC-AuCl and NHC-AuSR.
Walther, W. and Dada, O. and O’Beirne, C. and Ott, I. and Sanchez-Sanz, G. and Schmidt, C. and Werner, C. and Zhu, X. and Tacke, M.
Letters in Drug Design & Discovery 14
(2): 125-134.
2017
2014
In vitro and in vivo investigations into the carbene copper bromide anticancer drug candidate WBC4.
Walther, W. and Fichtner, I. and Hackenberg, F. and Streciwilk, W. and Tacke, M.
Letters in Drug Design & Discovery 11
(7): 825-832.
August 2014
2013
The activity of titanocene T against xenografted Caki-1 tumors.
Walther, W. and Fichtner, I. and Deally, A. and Hogan, M. and Tacke, M.
Letters in Drug Design & Discovery 10
(5): 375-381.
June 2013
2012
In vitro and in vivo investigations into the carbene silver acetate anticancer drug candidate SBC1.
Fichtner, I. and Cinatl, J. and Michaelis, M. and Sanders, L.C. and Hilger, R. and Kennedy, B.N. and Reynolds, A.L. and Hackenberg, F. and Lally, G. and Quinn, S.J. and McRae, I. and Tacke, M.
Letters in Drug Design & Discovery 9
(9): 815-822.
November 2012
2011
The antiangiogenic and antitumoral activity of titanocene Y* in vivo.
Fichtner, I. and Behrens, D. and Claffey, J. and Deally, A. and Gleeson, B. and Patil, S. and Weber, H. and Tacke, M.
Letters in Drug Design & Discovery 8
(4): 302-307.
May 2011
2008
Antitumor activity of oxali-titanocene Y in xenografted CAKI-1 tumors in mice.
Fichtner, I. and Behrens, D. and Claffey, J. and Gleeson, B. and Hogan, M. and Wallis, D. and Weber, H. and Tacke, M.
Letters in Drug Design & Discovery 5
(8): 489-493.
December 2008
Antitumor activity of Titanocene Y in xenografted PC3 tumors in mice.
Dowling, C.M. and Claffey, J. and Cuffe, S. and Fichtner, I. and Pampillon, C. and Sweeney, N.J. and Strohfeldt, K. and Watson, R.W. and Tacke, M.
Letters in Drug Design & Discovery 5
(2): 141-144.
March 2008
This list was generated on Wed Apr 24 11:21:24 2024 CEST.